Precision medicine drug developer Entact Bio has launched from stealth and raised USD 81 million in a Series A funding round co-led by Qiming Venture Partners USA and venBio Partners, with participation from new and existing investors. 

The new funds will be used toward advancing its proprietary platform, Encompass, to develop enhancement-targeting chimeric molecules that enhance the function of proteins.

Entact Bio discovers and develops drugs targeting proteins called deubiquitinases that enhance their function and restore cells’ health to treat certain cancers, inflammatory diseases, and rare genetic disorders associated with haploinsufficiency (where patients do not have enough of a protein in their cells to combat a disease). The Encompass platform combines biological, chemical, and computational tools to identify targets to treat complex diseases.